GELdom Condom
- User: Male
- Hormonal: Non-Hormonal
-
Delivery type:
- Barrier
-
Intended Duration:
- Pericoital
- Development Stage: Phase I
- Developer(s)/researcher(s): Eudaemon, University of Wollongong, Australia
Details
-
Mechanism of Action:
- Physical Barrier
- Inactive Materials: Hydrogel
- Regimen: On Demand
- MPT: Potential MPT
- Promising Attributes: Geldom aims to be more user-friendly than existing condoms. Hydrogel condoms can prevent pregnancy and STIs and could also have beneficial compounds – such as pleasure enhancers or anti-viral therapies – embedded in the material.
Product Status
Active/Recent Clinical Research - Preparing for Regulatory Submission
History
2014: University of Wollongong received funding from the Gates Foundation through its Global Grand Challenges program to conduct Phase 1 & 2 trials to develop a hydrogel condom.
2018: Eudaemon Technologies is founded as the commercialization start-up for the Geldom.
2022: Funding from the NSW Medical Devices Fund awarded to work towards quality manufacturing and regulatory approval.
2024: Eudaemon initiates and completes user experience trial, focused on user perception of the Geldom in comparison to traditional latex condoms. The trial protocol indicates that these studies will be used to inform the protocols of pivotal trials.